Erratum




In the April 2014 issue (Volume 28, number 2), in the article “The Role of Adenosine Signaling in Sickle Cell Therapeutics,” a potential conflict of interest for co-author Joel Linden was inadvertently omitted. Please note that Joel Linden, Ph.D. is an inventor on a patent issued to the University of Virginia, which claims the use of adenosine A2A agonists for the treatment of sickle cell disease; he owns shares in Adenosine Therapeutics LLC, which licensed this patent.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Sep 16, 2017 | Posted by in HEMATOLOGY | Comments Off on Erratum

Full access? Get Clinical Tree

Get Clinical Tree app for offline access